No Data
No Data
China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature a Plethora of Technological Products
Sinolink Securities: The pharmaceutical sector is expected to see an improvement in market conditions in the third quarter, and overall growth expectations for the second half of the year are optimistic.
Sinolink Securities released a research report stating that considering the improvement in the medical insurance settlement cycle, the expectation of policy improvement, and the recovery performance of the industry, as well as the fact that institutional medicine hold positions are at a low level, the medical sector will usher in an improved market situation in Q3.
Jianshi Technology-B (9877.HK): 6-month clinical data revealed, LuX-Valve Plus showcases global value.
Innovative medical instruments have always been the core focus of medical technology innovation and their development has always been a hot topic in the medical industry. In recent years, many Best-in-class and even pioneering First-in-class medical device projects with leading advantages have emerged in China. At the same time, domestic medical device companies are gradually narrowing the gap with their international peers in terms of R&D cycle, project scale, and technological innovation, and are beginning to shine on the global stage. Jienshi Technology's second-generation guided catheter tricuspid valve replacement system LuX-Valve Plus, developed through independent innovation research and development, is
The 6-month clinical data has shown strong performance, and the global strategy of Health World Technology B (09877) is steadily advancing.
With a wide layout in the high-growth heart valve track, and the upcoming commercial launch of multiple products, the growth potential of Jienshi Technology is already evident.
Director of Technology-B (09877.HK), Pan Fei, increased his shareholding by 2.3328 million shares.
According to the latest equity disclosure information from the Hong Kong Stock Exchange, on June 28, 2024, Healthsec-B (09877.HK) obtained an average price of HKD 3.922 per share and increased its shareholding by 2.3328 million shares, with a total investment of about HKD 9.1492 million. After the increase, the latest number of shares held by Pan Fei, an executive director, is 33.4525 million shares, and the shareholding ratio has increased from 10.03% to 10.78%.
Jenscare Scientific Releases Results of Study on Tricuspid Valve Replacement System in New York, Shanghai
No Data